Live Analyst Rating Changes 3019 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Tazeen Ahmad
BofA
Tazeen Ahmad
Wall Street Analyst
★★☆☆☆
#2217
on 13Foresight · ranked by our own returns
53%
Success Rate
-2.9%
Average Return
37 of 70 calls profitable · -32.5% vs benchmark
📈 Across the calls we could measure, roughly 53% of Tazeen Ahmad's ratings turned a profit when each position was held for 2 year — averaging -2.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

281 Buy 34 Hold 44 Sell
Tazeen's Stock Coverage 59 ratings · 2026-06-26
Company Date Position Consensus Price Target 2-Yr Return
ARGX
Argenx Se
Jun 24, 2026 BUY Strong Buy
-15.5% avg upside
46 analysts
$1016.00
14.34% Upside
+4.2%
OCUL
Ocular Therapeutix
Jun 22, 2026 BUY Strong Buy
+151.2% avg upside
21 analysts
$27.00
176.67% Upside
+0.0%
TSHA
Taysha Gene Therapies
Jun 22, 2026 BUY Strong Buy
+111.5% avg upside
21 analysts
$10.00
60.97% Upside
·
IMMX
Immix Biopharma
Jun 18, 2026 BUY Strong Buy
+83.3% avg upside
8 analysts
$27.00
177.71% Upside
·
ASND
Ascendis Pharma
Jun 16, 2026 BUY Strong Buy
+4.9% avg upside
24 analysts
$288.00
10.14% Upside
-0.0%
RYTM
Rhythm Pharmaceuticals
Jun 15, 2026 BUY Strong Buy
+12.0% avg upside
19 analysts
$149.00
37.63% Upside
+6.8%
BLTE
Belite Bio, Inc. ADR
Jun 15, 2026 BUY Strong Buy
+21.8% avg upside
10 analysts
$200.00
33.57% Upside
+1.1%
INCY
Incyte
Jun 15, 2026 BUY Buy
-7.1% avg upside
47 analysts
$124.00
15.29% Upside
+6.3%
APGE
Apogee Therapeutics
Jun 11, 2026 BUY Buy
-5.7% avg upside
19 analysts
$131.00
1.36% Downside
+48.3%
KYMR
Kymera Therapeutics
Jun 08, 2026 BUY Strong Buy
-13.8% avg upside
36 analysts
$110.00
5.63% Downside
+34.5%
FULC
Fulcrum Therapeutics
Jun 02, 2026 SELL Hold
+139.0% avg upside
14 analysts
$3.00
16.96% Downside
·
BCAX
Bicara Therapeutics Inc.
Jun 02, 2026 BUY Strong Buy
+18.5% avg upside
14 analysts
+27.3%
GILD
Gilead Sciences
Jun 02, 2026 BUY Strong Buy
-5.1% avg upside
66 analysts
$162.00
30.75% Upside
-2.4%
BNTX
BioNTech SE
Jun 01, 2026 BUY Strong Buy
+51.8% avg upside
26 analysts
$125.00
38.97% Upside
-0.9%
DNLI
Denali Therapeutics
May 22, 2026 BUY Strong Buy
+50.7% avg upside
24 analysts
+32.9%
ANRO
Alto Neuroscience, Inc.
May 21, 2026 BUY Strong Buy
+20.0% avg upside
13 analysts
$33.00
30.51% Upside
+15.7%
FATE
Fate Therapeutics
May 21, 2026 HOLD Buy
+535.5% avg upside
31 analysts
$2.20
17.60% Upside
-5.7%
STRO
Sutro Biopharma
May 21, 2026 SELL Strong Buy
+30.0% avg upside
20 analysts
+5.9%
PEPG
PepGen Inc.
May 21, 2026 SELL Strong Buy
+517.0% avg upside
9 analysts
$3.00
75.53% Upside
·
REGN
Regeneron
May 17, 2026 BUY Strong Buy
+24.5% avg upside
57 analysts
$860.00
38.60% Upside
-2.6%
AARD
Aardvark Therapeutics, Inc.
May 15, 2026 SELL Buy
+279.1% avg upside
12 analysts
$4.00
20.97% Downside
-0.0%
PHVS
Pharvaris
May 14, 2026 HOLD Strong Buy
+35.2% avg upside
14 analysts
$33.00
0.93% Downside
+8.8%
PTCT
PTC Therapeutics
May 14, 2026 BUY Strong Buy
-8.2% avg upside
29 analysts
+8.0%
SRRK
Scholar Rock Holding
May 08, 2026 BUY Strong Buy
+6.7% avg upside
23 analysts
$58.00
7.90% Upside
+5.9%
ANNX
Annexon Biosciences
May 08, 2026 BUY Strong Buy
+166.3% avg upside
13 analysts
$8.00
55.42% Upside
-13.9%
PRTA
Prothena
May 08, 2026 SELL Buy
+151.3% avg upside
14 analysts
$8.00
13.72% Downside
+20.9%
ACAD
ACADIA Pharmaceuticals
May 07, 2026 BUY Strong Buy
+51.9% avg upside
42 analysts
+14.4%
AMGN
Amgen
May 01, 2026 SELL Buy
-15.4% avg upside
57 analysts
$307.00
13.05% Downside
-6.0%
BCRX
BioCryst
Apr 16, 2026 BUY Strong Buy
+83.8% avg upside
24 analysts
-11.5%
RARE
Ultragenyx Pharmaceutical
Apr 16, 2026 BUY Strong Buy
+126.2% avg upside
36 analysts
-5.8%
ALNY
Alnylam Pharma
Apr 15, 2026 BUY Strong Buy
+17.4% avg upside
51 analysts
-14.1%
NBIX
Neurocrine
Apr 15, 2026 BUY Strong Buy
+4.0% avg upside
37 analysts
+20.4%
VRTX
Vertex Pharmaceuticals
Apr 15, 2026 BUY Strong Buy
-8.4% avg upside
61 analysts
$598.00
24.51% Upside
+5.7%
ARVN
Arvinas Holding Company
Mar 18, 2026 HOLD Strong Buy
+248.2% avg upside
27 analysts
$14.00
74.38% Upside
-26.3%
SRPT
Sarepta Therapeutics
Feb 25, 2026 SELL Buy
+272.0% avg upside
49 analysts
$19.00
18.70% Upside
+9.0%
GB:0QW0
arGEN X
Dec 18, 2025 BUY Strong Buy
-21.5% avg upside
24 analysts
·
NMRA
Neumora Therapeutics, Inc.
Apr 01, 2025 SELL Buy
+422.5% avg upside
11 analysts
$1.00
33.71% Downside
-102.2%
FDMT
4D Molecular Therapeutics
Sep 19, 2024 BUY Strong Buy
+205.5% avg upside
15 analysts
$79.00
585.84% Upside
-32.2%
ADCT
ADC Therapeutics
Oct 17, 2023 SELL Strong Buy
+468.8% avg upside
12 analysts
$1.00
3.83% Downside
-432.6%
GRTX
Galera Therapeutics
Aug 11, 2023 SELL Buy
+6568.5% avg upside
7 analysts
$0.50
461.82% Upside
·
PYXS
Pyxis Oncology
May 24, 2023 HOLD Strong Buy
+213.4% avg upside
13 analysts
$4.00
79.39% Upside
-63.2%
PRLD
Prelude Therapeutics
Mar 27, 2023 SELL Buy
+163.6% avg upside
7 analysts
$6.00
46.36% Upside
+89.1%
PRAX
Praxis Precision Medicines
Mar 06, 2023 HOLD Strong Buy
+66.2% avg upside
24 analysts
$22.50
93.12% Downside
+127.5%
SQZB
SQZ Biotechnologies
Dec 01, 2022 SELL Buy
+102677.7% avg upside
7 analysts
$20.00
83233.26% Upside
+24.3%
SRZN
Surrozen
Nov 16, 2022 SELL Buy
+41.2% avg upside
7 analysts
$1.00
95.92% Downside
+51.5%
TBPH
Theravance Biopharma
Apr 19, 2022 SELL Buy
+7.1% avg upside
18 analysts
$9.00
48.30% Downside
-3.0%
KALA
KALA BIO
Jul 21, 2021 BUY Strong Buy
+7491.0% avg upside
9 analysts
$8.00
213.73% Upside
-92.5%
MRNA
Moderna
Jan 25, 2021 HOLD Hold
+14.5% avg upside
38 analysts
$150.00
151.00% Upside
+31.3%
QNCX
Quince Therapeutics
Jun 03, 2019 HOLD Hold
+2193.2% avg upside
15 analysts
$28.00
2768.53% Upside
+87.7%
ALEC
Alector
Mar 04, 2019 BUY Hold
+497.5% avg upside
14 analysts
$26.00
1305.31% Upside
-22.1%
DBVT
DBV Technologies SA - American
Dec 20, 2018 SELL Buy
+50.6% avg upside
15 analysts
$8.00
49.98% Downside
+47.7%
PCRX
Pacira Pharmaceuticals
Oct 10, 2018 HOLD Buy
+60.5% avg upside
21 analysts
$48.00
97.01% Upside
+27.2%
MCRB
Seres Therapeutics
Aug 03, 2018 SELL Buy
+142.9% avg upside
11 analysts
$6.00
12.39% Downside
+45.8%
ACET
Adicet Bio
Feb 20, 2018 BUY Strong Buy
+218.8% avg upside
14 analysts
$23.00
191.22% Upside
-92.5%
SPRO
Spero Therapeutics
Nov 27, 2017 HOLD Buy
+574.3% avg upside
12 analysts
$16.00
692.14% Upside
-16.1%
RMTI
Rockwell Med
Nov 08, 2016 SELL Buy
+1365.1% avg upside
11 analysts
$5.00
668.19% Upside
+20.4%
CORT
Corcept Therapeutics
Jun 02, 2016 SELL Buy
-48.4% avg upside
15 analysts
$5.00
94.11% Downside
-196.0%
INVA
Innoviva
Sep 09, 2015 SELL Buy
+22.3% avg upside
12 analysts
$13.00
44.42% Downside
-29.2%
GLNG
Golar LNG
Sep 19, 2014 BUY Strong Buy
-12.8% avg upside
22 analysts
$110.00
119.75% Upside
-67.9%
🔒 54 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Tazeen Ahmad — Frequently Asked Questions
How accurate are Tazeen Ahmad's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Tazeen's ratings were profitable over a one-year hold, with an average return of -0.7% per rating, or -25.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Tazeen ranked on 13Foresight?
Tazeen Ahmad is currently ranked #2217 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Tazeen cover?
Tazeen most recently has ratings on ARGX, OCUL, TSHA, IMMX, ASND, RYTM, BLTE, INCY, APGE, KYMR, FULC, BCAX and 47 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.